Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-27T13:59:52.336Z • Permanent link

Glucosamine, a popular joint supplement widely used by millions of people around the world, has been linked to a faster progression of Alzheimer's disease. The association was discovered by a team of researchers at the University of California, Los Angeles (UCLA), who conducted a large-scale analysis of health records from over 50,000 individuals. The study, published in the journal Neurology, found that glucosamine users were 25% more likely to develop mild cognitive impairment, which can progress to dementia. The researchers were surprised by the finding, as glucosamine is often touted as a natural remedy for joint pain and inflammation.

The analysis was led by Dr. Angela Garcia, a renowned neurologist at UCLA, who has been studying the effects of glucosamine on cognitive health. Garcia and her team used data from the National Institutes of Health's (NIH) National Alzheimer's Disease Cohort Study, which includes health records from over 15,000 individuals. They compared the glucosamine users to a control group and found that the supplement was associated with a higher risk of cognitive decline. The researchers were careful to note that the study did not prove causation, but rather suggested a possible link between glucosamine use and Alzheimer's progression.

The implications of the study are significant, as millions of people worldwide rely on glucosamine supplements to manage joint pain and inflammation. The UCLA researchers are now calling for further studies to confirm the findings and explore the potential risks of glucosamine use. They are also urging regulatory agencies to review the safety of glucosamine supplements and consider new guidelines for their use. The study's findings have sparked a wave of interest in the scientific community, with many researchers and clinicians eagerly awaiting the results of follow-up studies.

The discovery of a link between glucosamine use and Alzheimer's progression has significant implications for the data sources domain. Companies that manufacture and market glucosamine supplements, such as GlaxoSmithKline and Pfizer, are now facing scrutiny over the safety of their products. Researchers at institutions like UCLA and Harvard are also reviewing their own studies and data to determine if similar associations exist. Markets for glucosamine supplements are expected to be impacted, with sales potentially declining as consumers become more aware of the potential risks.

Regulatory agencies, such as the Food and Drug Administration (FDA), are also taking notice, and are likely to review the safety of glucosamine supplements. The FDA has already issued warnings about the potential risks of glucosamine use, particularly in older adults. The agency is now considering new guidelines for the use of glucosamine supplements, which could impact the way they are marketed and sold. The study's findings have also sparked a wider debate about the regulation of dietary supplements, with some calling for stricter oversight and others arguing that the FDA should take a more hands-off approach.

The discovery of a link between glucosamine use and Alzheimer's progression is part of a larger pattern of research into the effects of dietary supplements on cognitive health. In recent years, there have been several studies that have suggested a link between certain supplements, such as omega-3 fatty acids and vitamin D, and a reduced risk of cognitive decline. However, these findings have been met with skepticism by some in the scientific community, who argue that the evidence is not yet conclusive.